Oncology – Gastrointestinal
Preliminary results of a RCT | Once-only colonoscopy vs. two rounds of fecal immunochemical testing 2 years apart for colorectal cancer screening.
20 Sep, 2022 | 13:29h | UTCOnce-only colonoscopy or two rounds of faecal immunochemical testing 2 years apart for colorectal cancer screening (SCREESCO): preliminary report of a randomised controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary: Two Rounds of FIT vs Single Colonoscopy as a One-time CRC Screening – Medscape (free registration required)
RCT | Short-term outcomes of laparoscopy-assisted vs. open surgery for patients with low rectal cancer.
16 Sep, 2022 | 12:58h | UTC
Commentary on Twitter
The LASRE trial established the short-term oncologic safety of using laparoscopic surgery for low rectal cancer. The rate of complete total mesorectal excision was practically identical with laparoscopic surgery (85.3%) vs open surgery (85.8%). https://t.co/Ova2HnfO6p #Research
— JAMA Oncology (@JAMAOnc) September 15, 2022
RCT | Robotic vs. laparoscopic surgery for middle and low rectal cancer.
15 Sep, 2022 | 13:09h | UTCRobotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentaries:
Robotic Surgery Tops Laparoscopic Surgery for Middle and Low Rectal Cancer — Randomized trial shows fewer positive circumferential resection margins with robotic technique – MedPage Today (free registration required)
Commentaries on Twitter
RCT: Robot versus laparoscopic surgery for middle and low rectal cancer – 11 hospitals, 1171 patients
🤖 vs lap:
CRM+ 4% vs 7%
Complications 16% vs 23%
APR 17% vs 23%
Conversion 2% vs 4%https://t.co/3mU9m7sDVB#colorectalcancer #colorectalsurgery— Ville Sallinen (@villesallinen) September 8, 2022
New research online – Feng et al – Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trialhttps://t.co/B60DV5e4iJ#GITwitter @OncoAlert #rectalcancer #crcsm #SoMe4Surgery pic.twitter.com/9NoXXyCGwM
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) September 8, 2022
RCT | Extended duration thromboprophylaxis (continued for 56 days postoperatively) is not beneficial after surgical resection of colorectal cancer.
14 Sep, 2022 | 13:22h | UTC
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma.
11 Sep, 2022 | 22:50h | UTCAASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma – Hepatology
RCT | Ripretinib vs. Sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib.
8 Sep, 2022 | 14:24h | UTC
Commentary on Twitter
👀 INTRIGUE Trial: Ipretinib not superior to sunitinib but demonstrates longest median progression free survival ever in advanced #GastrointestinalStromalTumor ➡️ https://t.co/aUNdvXaQcH #GIST #scmsm @seppobauer pic.twitter.com/pPfph6A8Lr
— Journal of Clinical Oncology (@JCO_ASCO) August 24, 2022
Single-arm, phase 2 study | Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
6 Sep, 2022 | 14:24h | UTCGalunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries:
5-year follow-up of a RCT | Five-year outcomes of FOLFIRINOX vs. Gemcitabine as adjuvant therapy for pancreatic cancer.
5 Sep, 2022 | 14:26h | UTCFive-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Updated 5-year results of the Unicancer PRODIGE 24/CCTG PA6 trial confirmed the significant improvement in all outcomes, including overall survival, with mFOLFIRINOX regimen compared to gemcitabine in adjuvant setting for pts w #pancreaticcancer. https://t.co/rCFntho0f1 #GICSM pic.twitter.com/VAVBD7o6kc
— JAMA Oncology (@JAMAOnc) September 1, 2022
Systematic Review | Contrast‐enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.
5 Sep, 2022 | 14:13h | UTC
Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score
2 Sep, 2022 | 13:03h | UTC
Single-arm phase 2 study | Neoadjuvant Nivolumab plus Ipilimumab and Adjuvant Nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma.
1 Sep, 2022 | 11:47h | UTC
Guideline | Fecal immunochemical testing in patients with signs or symptoms of suspected colorectal cancer.
31 Aug, 2022 | 11:52h | UTCCommentary: Guidelines update: use of FIT in colorectal cancer referrals – PULSE
Meta analysis of randomized trials | Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer.
30 Aug, 2022 | 12:07h | UTCAssociation of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials – JAMA Oncology (free for a limited period)
Commentary on Twitter
In this meta-analysis of >11,000 patients with advanced gastroesophageal cancer, tissue PD-L1 expression — more than other variables besides microsatellite-high — identified varying degrees of benefit from immunotherapy-containing therapy. https://t.co/oUEDIEqLFj
— JAMA Oncology (@JAMAOnc) August 25, 2022
RCT | Colorectal Endoscopic Stenting Trial (CReST) for obstructing left-sided colorectal cancer.
30 Aug, 2022 | 11:58h | UTC
Cohort Study | Outcomes of patients with sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm under active surveillance.
30 Aug, 2022 | 11:57h | UTC
Clinical practice guidelines for intrahepatic cholangiocarcinoma.
26 Aug, 2022 | 13:20h | UTC
Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus.
26 Aug, 2022 | 13:19h | UTC
Network M-A | Efficacy of various adjuvant chemotherapy methods in preventing liver metastasis from potentially curative colorectal cancer.
25 Aug, 2022 | 12:01h | UTC
Review | New concepts in the treatment of hepatocellular carcinoma.
24 Aug, 2022 | 13:56h | UTCNew concepts in the treatment of hepatocellular carcinoma – UEG Journal
Case-control study | Assessment of outcomes from 1-year surveillance after detection of early gastric cancer among patients at high risk.
23 Aug, 2022 | 13:11h | UTCCommentary: Intensive Endoscopy Might Not Be One-and-Done for Gastric Cancer Surveillance — High-risk group had similar new lesion detection rates initially and at 15 months – MedPage Today (free registration required)
Commentary on Twitter
Among patients with a high risk of gastric cancer, 1-year surveillance was warranted even after intensive endoscopic examination using both white light and narrow-band imaging. https://t.co/3KIghTavjb
— JAMA Network Open (@JAMANetworkOpen) August 19, 2022
Single-arm Phase 2 study | Neoadjuvant chemotherapy, excision, and observation for early rectal cancer.
23 Aug, 2022 | 12:53h | UTC
Commentary from the author on Twitter (thread – click for more)
Pleased to share our @CDNCancerTrials NEO Trial results: 79% of patients with cT1-3bN0 #rectalcancer had organ sparing therapy with 3 mo of FOLFOX/CAPOX and transanal surgery. @drcarl_vancouvr @JCO_ASCO @OncoAlert https://t.co/gfcywHk7Y0
— Hagen Kennecke (@HKennecke) August 18, 2022
RCT | Effectiveness of Etoposide and Cisplatin vs. Irinotecan and Cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system.
22 Aug, 2022 | 11:54h | UTC
Commentary on Twitter
JCOG1213 (TOPIC NEC), the first randomized phase III trial in advanced neuroendocrine carcinoma of the digestive system, shows no significant difference in overall survival for etoposide+cisplatin versus irinotecan+cisplatin therapy https://t.co/JTELRlzTzi #GICSM pic.twitter.com/AQT8U4yd3l
— JAMA Oncology (@JAMAOnc) August 18, 2022
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.
18 Aug, 2022 | 12:47h | UTCCommentaries:
Trastuzumab deruxtecan-related ILD/pneumonitis characterized – medwire News
Review | Barrett Esophagus.
17 Aug, 2022 | 14:26h | UTCBarrett Esophagus: A Review – JAMA (free for a limited period)
Audio clinical review: Barrett Esophagus – JAMA
M-A | Use of folic acid supplementation to halt and even reverse the progression of gastric precancerous conditions.
11 Aug, 2022 | 11:51h | UTCCommentary: Can Folic Acid Halt or Reverse Progression of Gastric Precancerous Conditions? – Medscape (free registration required)